VentriPoint Diagnostics Ltd V.VPT

RE:With Huhg and Bart initiates 👀GranhamB sad manipulator

[jopatclo]

Interesting https://cdn-ceo-ca.s3.amazonaws.com/1huppni-GEHealthcare_Ventripoint_Intel_Briefing_20230208%20-%20Copy.pdf The Ventripoint – GE Partnership

Though details of the partnership have been kept under wraps, it is possible to make inferences about

how the relationship came to be – and perhaps the significance of it - based on the academics who have

studied the VMS+ and direct connections to cardiac ultrasound innovation at GE.

The ProCardio Center for Innovation in Oslo appears to have a significant partnership with GE

Healthcare with the goal of advancing cardiac technology through the Edison program1

. Ventripoint is an

Edison Partner2

. ProCardio is located in at the Rikshospitalet in Oslo, the site of a Ventripoint VMS+

placement3

.

The VMS+ has been studied by persons at the hospital including H. Brun4

, and senior cardiologists

associated to Rikshospitalet/ProCardio have direct relationships to persons who use/study VMS+.

Examples include leaders of ProCardio: Edvardsen who has published with Brun and authored at least 5

papers with Mertens (one of VMS+’s most prolific researchers); and Samset who has published with

Almeida5

. Based on LinkedIn and other open-source information, Samset appears to have a significant

senior role at GE in the advancement of innovative AI cardiology technology through the Edison

program6

. Almeida is particularly noteworthy as he published a paper that included a review of VMS+

and as of 2022 worked at GE Vingmed in Norway. GE’s Norway location appears to be a major hub for

its cardiac ultrasound business7

. Furthermore, a VMS+3.0 was placed King’s College London8

 and key

user Monaghan has published with both Samset and Almeida9

.

Another significant link is that the GE Norway official quoted in the Ventripoint/GE release (Mcleod) has

also published with Brun (VMS+ researcher). Put a different way, the person initially chosen to represent

this relationship for GE had a direct previous connection to VMS. It is possible, given the timing of

Mcleod’s presence at ProCardio10, that this expert could have had direct experience using the

technology.

GE Healthcare is active on Linkedin and produces a significant amount of training content involving

cardiologists11. Ventripoint Clinical Advisor Banchs12 is involved in GE echocardiography training.

Similarly experts Delgado and Sitges have written chapters1314 in echocardiography textbooks that have

discussed VMS (aka Knowledge-Based Reconstruction) and both appear to be involved in GE echo

training.

What does this mean? The information summarized above and in the associated chart suggests that a

major research institution/hospital (ProCardio/Rikshospitalet) responsible for the advancement of 

1 Annual-report-2021-FINAL.pdf (heart-sfi.no)

2 Ventripoint Collaborates with GE Healthcare to Bring More Functionality to its Cardiac Ultrasound Devices (thenewswire.com)

3 VentriPoint Diagnostics Ltd. (VPTDF) Technology Now Used by Hospitals around the World - QualityStocks

4 Ventripoint VMS(TM) Heart Analysis System Used to Monitor Therapy in Pulmonary Hypertension and Valve Replacement in Congenital Heart

Disease (yahoo.com)

5 Left atrial volumetric assessment using a novel automated framework for 3D echocardiography: a multi-centre analysis - PubMed (nih.gov)

6 GE Healthcare, American College of Cardiology unite toward AI-powered cardiac care | Healthcare IT News

7 GE sees strong future with its ultrasound business (jsonline.com)

8 Kings College London Receives VMS+3.0 Ventripoint Whole Heart Analysis System (thenewswire.com)

9 Left atrial volumetric assessment using a novel automated framework for 3D echocardiography: a multi-centre analysis - PubMed (nih.gov)

10 SFI CCI Final Report, trykk.pdf (heart-sfi.no)

11 LinkedIn searches for “GE Healthcare”, filtered by posts

12 Ventripoint Welcomes Dr. Jose Banchs as New Clinical Advisor (thenewswire.com)

13Assessing the Right Ventricle | SpringerLink

14 Speckle Tracking | 18A | v3 | 3D Echocardiography | Nicolas Duchateau, (taylorfrancis.com) cardiac technology for GE has experts (some of whom also work for GE) who were already likely familiar

with VMS prior to the Ventrpoint-GE announcement, both through the placement of the device at the

facility and via direct relationships with other cardiac experts who use/publish on VMS. Given the

absence of information on the partnership, this analysis could suggest that the relationship is credible

and significant, considering the number and quality of experts familiar with Ventripoint, and closely

linked to GE.

PLEASE READ: The information shown above and in the associated chart is based on extensive searches

of publicly available information from academic publications, LinkedIn, and websites. The analysis does

not make any predictions about the future direction/success of Ventripoint, and the inferences made

are highly speculative and could be incorrect.

jopatclo wrote:

For GranhamB see remember  with Huhg and Bart initiates( Insiders buy on the one market for one reason, they think its going up Insiders know!)why you are a manipulator Granhamb.

For new people who watch Ventripoint (ATTENTION GranhamB. Sad character to have several fake accounts to denigrate Ventripoint and Dr. Adams with this technology that saves lives, they are vultures.)

Hugh MacNaughtHugh MacNaught • Following • FollowingPresident and CEO at Ventripoint Diagnostics Ltd.President and CEO at Ventripoint Diagnostics Ltd.1mo • 1 month ago

 

Great points Bart. Faster, less expensive and providing cMRI levels of accuracy make VMS+ a compelling option for clinical trials, particularly those monitoring right ventricle volumes and ejection fractions. AI enhanced echo is a more patient-friendly modality which improves patient recuitment and compliance thereby improving efficiency and reducing risk.

Bart HendriksBart Hendriks • Following • FollowingMotivational Speaker, CEO, Mentor, and Strategic Advisor in start- and scale-ups, with expertise in pioneering clinical AI applications and cutting-edge technology.Motivational Speaker, CEO, Mentor, and Strategic Advisor in start- and scale-ups, with expertise in pioneering clinical AI applications and cutting-edge technology.1mo • 1 month ago

Revolutionizing Cardiac Diagnostics: The Cost-Effective and Inclusive Power of Ventripoint VMS+ Over Traditional MRI in Clinical Trials

In the realm of cardiac diagnostics, the Ventripoint VMS+ system emerges as a transformative tool, offering a unique blend of efficiency, cost-effectiveness, and patient inclusivity. Here’s why researchers and clinicians are opting for VMS+ over traditional cardiac MRI:

High Precision with Lower Costs: Traditional cardiac MRIs are known for their steep costs, encompassing expensive imaging equipment, specialized facilities, and prolonged testing times. In contrast, the Ventripoint VMS+ leverages standard echocardiography equipment to provide MRI-equivalent heart measurements, significantly reducing costs and making it a financially viable option for extensive clinical trials.

Enhanced Efficiency: The lengthy process required for MRI scans often leads to increased trial durations and higher costs. VMS+ simplifies cardiac assessment, enabling rapid, on-the-spot evaluations and accelerating the trial process.

Improved Patient Experience: The daunting nature of MRI scans can deter patient participation. The non-invasive and patient-friendly approach of the VMS+ increases comfort and compliance, which is crucial for successful clinical trials.

Magnetless Technology: The VMS+ system utilizes magnetless technology, making it a safe option for patients with pacemakers or other metallic implants who are typically excluded from MRI studies. This inclusion broadens the potential patient population for clinical trials, enhancing the diversity and applicability of research findings.

Reliable Data Collection: VMS+'s advanced algorithms deliver consistent and repeatable cardiac measurements, providing robust and reliable data essential for precise clinical analysis.

Dramatic Cost Reductions: Clinical trials can achieve significant cost reductions by integrating the VMS+ system. The savings come not only from eliminating expensive MRI scans but also from reduced patient attrition and more efficient data collection processes.

Accessibility and Portability: The VMS+'s portable nature expands its usability across diverse clinical settings, further driving down logistical costs and facilitating broader geographic reach in trials.

In clinical trials, where managing costs without compromising quality is paramount, the Ventripoint VMS+ offers an innovative, cost-effective, and inclusive solution. Connect with us to explore how VMS+ is reshaping cardiac diagnostics, making advanced technology accessible and affordable for a wider range of patients!

hashtag#Ventripoint hashtag#ClinicalTrials hashtag#CardiacHealth hashtag#Innovation hashtag#MedicalDevices hashtag#Cardiology hashtag#PacemakerSafe hashtag#CRO